Effects of local heparin administration on coronary thrombin activity during percutaneous transluminal coronary angioplasty

Catheterization and Cardiovascular Interventions

Volumn 48, Issue 1, 1999, Pages 84-88

  Laskey, Warren K ^a,b   Zawacki, Kevin ^a   Lim, Richard ^a   Herzog, William ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; FIBRINOPEPTIDE A; HEPARIN; THROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY SINUS; DRUG DELIVERY SYSTEM; FEMALE; FEMORAL ARTERY; HEPARINIZATION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBIN III; CORONARY VESSELS; FEMALE; FIBRINOPEPTIDE A; HEPARIN; HUMANS; MALE; THROMBIN; WHOLE BLOOD COAGULATION TIME;

EID: 0032881669     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-726X(199909)48:1<84::AID-CCD17>3.0.CO;2-O     Document Type: Article

References (19)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
2. Barnathan ES, Schwartz S, Taylor L, Laskey WK, Kleaveland SP, Kussmaul WG, Hirshfield JW Jr. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134.
3. Laskey MA, Deutsch E, Hirshfeld JW, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-182.
4. Laskey MA, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on PTCA outcome in unstable angina pectores. Am J Cardiol 1990;65:1425-1429.
5. Moura A, Lam JYTM, Herbert D, Kermode JR, Grant GW, Robitaille D, Klein EJ, Yock PG, Simpson JB, Kaplan AV. Intramural delivery of agent via a novel drug delivery sleeve: histologic and functional evaluation. Circulation 1995;92:2299-2305
6. Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP, Jr. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity. J Clin Invest 1976;58:1136-1144.
7. Tolefson DM, Blank MK. Detection of a new heparin dependent inhibitor of thrombin in human plasma. J Clin Invest 1981;68:589-596.
8. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winkers KJ. Association of heparin resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-2071.
9. Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, Bossi IM, Mannucci PM. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997;29:13-20.
10. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, Ardissino D, Ambrose JA. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-1491
11. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993;88:2728-2734.
12. Watkins MW, Luetner PA, Schneider DJ, Witner WT, Vaitkus PT, Sobel BE. Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. Cathet Cardiovasc Diagn 1998;44:257-264.
13. Scharf RE, Tomes A, Marzec VM, Tierstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty damaged coronary arteries: flow cytometric detection. Arterioscler Thromb 1992;12:1475-1487.
14. Tschoepe D, Schultheib HP, Kolarov P. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 199;88:37-42.
15. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin anti-thrombin III but is susceptible to inactivation by anti-thrombin III independent inhibitors. J Clin Invest 1990;86:385-391.
16. Ferguson JJ. Conventional anti-thrombotic approaches. Am Heart J 1995;130:651-657.
17. Rath B, Bennett DM. Monitoring the effect of heparin by measurement of activated clotted time during and after percutaneous transluminal coronary angioplasty. Br. Heart J 1990;63:18-21.
18. Bartorelli AL, DeCesare NB, Kaplan AV, Fabbiocchi F, Montorsi P, Squadroni L, Galli S, Sganzerla P, Loaldi A. Local heparin delivery prior to coronary stent implantation: acute and six month clinical and angiographic results. Cathet Cardiovasc Diag 1997;42: 313-320.
19. Tanguay JF, Kruse KR, Kaplan AV, Armstrong BA, Grant GW, Virmani R, Phillips HR, Zidar JP. Local delivery of heparin prior to intracoronary stenting reduces platelet deposition. J Am Coll Cardiol 1996;27:85A.